Elisabeth Reiser1, Stefanie Aust1, Veronika Seebacher1, Alexander Reinthaller2, Samir Helmy-Bader1, Richard Schwameis1, Christoph Grimm3, Stephan Polterauer2. 1. Department of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Center, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. 2. Department of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Center, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute for General Gynecology and Experimental Gynecologic Oncology, Vienna 1090, Austria. 3. Department of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Center, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. Electronic address: christoph.grimm@muv.ac.at.
Abstract
OBJECTIVE: To evaluate C-reactive protein (CRP) serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal masses. METHODS: CRP serum levels of 1843 adnexal masses and subsequent surgery were investigated (patients with benign ovarian tumors: n=1423; borderline tumor of the ovary [BTO]: n=83; EOC: n=337). Test characteristics and predictive values of CRP serum levels were investigated by univariate analysis and multivariate binary logistic regression models. RESULTS: Median (interquartile range) serum CRP levels in patients with benign ovarian tumors, BTO, and EOC were 0.4 (0.1-0.6)mg/dL, 0.5 (0.2-0.9)mg/dL, and 1.6 (0.5-5.4)mg/dL, respectively (p<0.001). Sensitivity and specificity of the combination of CRP and CA-125 was 80.1% and 90.8%, negative predictive value (NPV) and positive predictive value (PPV) was 92.2% and 76.9%, respectively. In univariate and multivariate analysis, CRP serum levels were independently associated with presence of BTO and EOC (HR 6.7 [5.2-8.5], p<0.001 and HR 2.2 [1.4-3.3], p<0.001). The combination of CRP and CA-125 serum levels resulted in a number needed to treat of 2.11 to detect one case of EOC or BTO. CONCLUSION: CRP serum levels independently predicted the presence of BTO and EOC in patients with suspicious adnexal masses. CRP serum levels seem to be of additional value to CA-125 in the preoperative differential diagnosis of adnexal masses and might be particularly in combination with CA-125 clinically useful.
OBJECTIVE: To evaluate C-reactive protein (CRP) serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal masses. METHODS:CRP serum levels of 1843 adnexal masses and subsequent surgery were investigated (patients with benign ovarian tumors: n=1423; borderline tumor of the ovary [BTO]: n=83; EOC: n=337). Test characteristics and predictive values of CRP serum levels were investigated by univariate analysis and multivariate binary logistic regression models. RESULTS: Median (interquartile range) serum CRP levels in patients with benign ovarian tumors, BTO, and EOC were 0.4 (0.1-0.6)mg/dL, 0.5 (0.2-0.9)mg/dL, and 1.6 (0.5-5.4)mg/dL, respectively (p<0.001). Sensitivity and specificity of the combination of CRP and CA-125 was 80.1% and 90.8%, negative predictive value (NPV) and positive predictive value (PPV) was 92.2% and 76.9%, respectively. In univariate and multivariate analysis, CRP serum levels were independently associated with presence of BTO and EOC (HR 6.7 [5.2-8.5], p<0.001 and HR 2.2 [1.4-3.3], p<0.001). The combination of CRP and CA-125 serum levels resulted in a number needed to treat of 2.11 to detect one case of EOC or BTO. CONCLUSION:CRP serum levels independently predicted the presence of BTO and EOC in patients with suspicious adnexal masses. CRP serum levels seem to be of additional value to CA-125 in the preoperative differential diagnosis of adnexal masses and might be particularly in combination with CA-125 clinically useful.
Authors: Chiara Di Tucci; Daniele Di Mascio; Michele Carlo Schiavi; Giorgia Perniola; Ludovico Muzii; Pierluigi Benedetti Panici Journal: Case Rep Obstet Gynecol Date: 2018-07-11
Authors: Christine Bekos; Christoph Grimm; Lisa Gensthaler; Thomas Bartl; Alexander Reinthaller; Richard Schwameis; Stephan Polterauer Journal: Geburtshilfe Frauenheilkd Date: 2022-01-10 Impact factor: 2.915